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Abstract
Background: The aim of this double-blind randomized study is to test the efficacy of a radio electric stimulator
device using an auricular reflex therapy protocol for stress-related symptoms.
Methods: The study has been carried out on 200 subjects (138 females, 62 males) that voluntarily came to our
Institute declaring to “feel stressed”.
The participants were randomly allocated with a computerized procedure: 150 were treated with auricular thera-
peutic protocol with radio electric stimulator device (REAC) and 50 were treated with an inactivated, placebo REAC.
Psychological stress was evaluated trough the self-administered questionnaire Psychological Stress Measure (PSM).
Assessment data were collected at 2 time points: before the treatment (T0) and immediately after the therapy
cycle of 18 sessions about 4 weeks later (T1).
Results: In the group treated with REAC, the psychometric evaluation after the therapy’s cycle showed a significant
reduction of PSM total scores, from 107.8 ± 23,13 at T0 to 87.1 ± 16,21 at T1 (p < 0.5), while in the control group
no significant variation in decreasing stress-related symptomatology has been noted (107.86 ± 25,80 at T0 and
106.32 ± 25,88 at T1 (p = NS).
Conclusions: The protocol of the auricular treatment with REAC seems to reduce the subjective perception of
stress, as “psychometrically” demonstrated by the significant reduction in PSM test total score. This therapeutical
procedure also provides a non invasive, not painful and very simple innovative approach to treat the widely
diffused stress related disorders.
Trial Registration: This trial has been registered in the Australian New Zealand Clinical Trials Registry (ANZCTR)
with the number: ACTRN12607000529448
Background
Environmental stress produces important effects on the
individual health. Chronic social stress is one of the
most important factors [1-3] responsible for worsening
stress related symptoms [4,5] and for triggering pre-
viously undetected mood disorders [6,7]. In recent years,
the effects of social stress on psychopathologies develop-
ment have been thoroughly investigated [4,6,8,9]. It has
been hypothesized that life stress alters the dynamic
regulation of the autonomic, neuroendocrine [10] and
immune systems [11].
The Central Nervous System (CNS), as the main bio-
logical target of stressful events [2,7], has continuously
to change to accommodate to rapid environmental
development. This imperceptible adaptation process is
detrimental to health and quality of life [12].
Allostasis represents the adaptation process of the
complex physiological system to physical, psychosocial
and environmental changes or social stress [13-15]. The
term “allostatic load” was coined by McEwen and refers
to physiological costs of chr o n i ce x p o s u r et on e u r a lo r
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state is unable to guarantee the good management of
the physiological systems and consequently the health
status and the individual’s well-being, and this phenom-
ena often leads to the development of psychological and
psychiatric symptoms [18-32]. Among the several non-
pharmacological strategies today available to reduce
and/or to treat the symptomatic effects of the stress and
to improve the allostatic response [33,34], of particular
interest appears the use of electrical and electromagnetic
stimulation [35], also exploiting the “classical” acupunc-
ture points [36,37]. The REAC uses a new kind of non
invasive and not painful electromagnetic stimulation
that produces a weak radio frequency current (RFC)
easily applied with a probe to specific somatic reflex
points [38].
Aim of the Study
The purpose of this study is to verify if the use of REAC
could reduce the subjective perception of stress and
stress-related symptoms, evaluated by PSM at T0 and
T1 [39-41]. PSM also allows the precise classification of
the subject studied on a stress well-being scale, to accu-
rately assess the effectiveness of the treatment.
Materials and methods
The study was performed in accordance with the
Declaration of Helsinki, with the Societa di Ottimizza-
zione Neuro Psico Fisica e CRM Terapia institutional
ethics committee approval, and all subjects provided
written informed consent. A double-blind, randomized
and placebo-controlled trial was performed to investi-
gate the effectiveness of REAC auricular treatment in
reducing of self perception of stress and stress-related
symptoms and, consequently, the PSM total score.
Participants
The study has been carried out on 200 subjects (138
females, 62 males), that voluntarily came to our Institute
suffering from a broad stress-related range of psycholo-
gical symptoms such as affective-emotional reactions i.e.
sadness, irritability, anger, depression, poor concentra-
tion and attention, insecurity, anxious and apprehensive
condition, depression, sleep disorders, generalized mus-
cle tension, gastro intestinal disorders, headaches. Parti-
cipants were properly informed about significance and
objectives of the study and then they completed, in
association with the Project Director prior to enrolment,
a written consent form. For all participants were prop-
erly collected and detailed: general demographic infor-
mation, background characteristics, treatments history,
drug history survey and medical examination.
The participants, selected after a clinical screening,
have been allocated randomly into 2 socially and
demographically matched groups with a computerized
procedure: Group A, treated with “active” REAC (N =
150, 46 males, age = 49.8 ± 13.7 yrs and 104 females,
age = 48.3 ± 12.5 yrs), and Group B, treated with deacti-
vated-placebo REAC (N = 50, 16 males, age = 52.7 ±
17.7 yrs, and 34 females, age = 50.6 ± 15.1 yrs). The 3:1
proportion between cases and controls has been selected
only on the base of the main “typology” of the people
who require a clinical treatment in our Institute:
“stressed” subjects are more numerous than “non-
stressed” subjects.
REAC protocol consists in 18 session each one lasting
3,5 seconds, administered in about 4 weeks.
All subjects were over 18 years old, declaring to suffer
from stress-correlated psycho-physical conditions, as
demonstrated by a clinical evaluation and the PSM total
score >45. No history of drug abuse, nor severe mental
illness or personality disorder according to DSM-IVTR
criteria (as valuated by a psychiatrist, also trough the
administration of SCL-90 scale in the “doubt” subjects)
and no psychopharmacological-psychological interven-
tions has been reported.
Exclusion criteria for both groups: diagnosis of axis I-
II psychiatric disorders, organic CNS pathology, preced-
ing skull traumas with loss of conscience longer than 5
minutes, dementia, alcohol dependence, current therapy
with medications known to affect cognitive functioning.
Randomization
The study has been setted in 4 rooms. In 3 of the 4
rooms has been activate REAC and in the other 1 the
placebo-REAC. The physicians that have participated in
the treatment’s administration turned in the different
rooms, using both “active” and “inactive” REAC but they
didn’tk n o wi ft h e yu s e da na c t i v eo rp l a c e b oR E A C .
The computerized randomization process, managed by
an external operator to the study, foresaw the assign-
ment of the subjects to each room. The target sample
size 200, divided in the 4 rooms, has produced 4 sub-
groups, each composed by 50 people (n = 50 × 3 = 150
treated, n = 50 × 1 = 50 placebo).
Instruments and materials
Psychological Test
PSM, a standardized and validated self-reporting test for
the measurement of psychological stress was adminis-
tered to all subjects, before (T0) and after REAC treat-
ment (T1) [39-41]. PSM consists of 49 items for the
self-evaluation aimed at identifying different “clusters” of
symptoms such as loss of control, irritability, psycho-
physiological sensations, confusion, anxiety, depression,
physical pain, hyperactivity and agitation. The patient
must answer to the various items ranking the intensity
of his psychological stress condition (very much = 4,
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of subjectivity of evaluation, this self-administered ques-
tionnaire was preferred with the aim to reduce the
increasing of psychic and somatic anxiety levels and
“arousal” inevitably due to a “direct” subject-physician
interaction.
Description of the Radio Electric Asymmetric Conveyer REAC
The REAC is an innovative medical device [38] aimed
to promote a reduction of the dysfunctional modifica-
tions in the Nervous System induced by stress and psy-
chological factors [42]. REAC uses the radio electric
effects produced by the interaction between the electro-
magnetic field of the human body (~30-300 GHz, of
about 3 mW/m2) [43] and the field produced by the
instrument (2.4 or 5.8 or 10.5 GHz, measurable from
the emitter about 0.1 mW/m2) which lasts approxi-
mately a few milliseconds. This radio electric interaction
is received by a probe (conveyer) placed on specific
points of the auricular pinna giving a radio electric sti-
mulation. The inactive REAC is the exact same
machine, but has a modified probe. The instrument that
we used is registered under the trademark Convoglia-
tore di Radianza Modulante - CRM produced by
ASMED, Italy.
Description of auricular therapy protocol
The auricular treatment protocol has been conceived by
the authors and called Neuro Psycho Physical Optimiza-
tion (NPPO). The REAC probe was applied to 7 specific
points of the auricular pinna: “shen men”,k i d n e y ,s t o -
mach, heart, occiput, ipotalamus, prefrontal cortex.
Eighteen sessions of NPPO with REAC were adminis-
tered on alternate days, in about four weeks, to each
patient. Each therapeutic session lasted approximately 3
seconds. The protocol is painless, non-invasive, and
without known side effects.
Statistical analysis
Statistical analysis were performed using Statistical
Package for Social Science (version 13). The McNemar
test is used to compare the relevant frequencies for data
resulting from PSM test in patients belonging to group
A and to group B before and after NPPO with REAC.
Also Wilcoxon Signed Ranks Test and Sign test are
used to evaluate the related samples of Total points
resulting from PSM test of both groups. All results of p
< 0.05 were considered statistically significant.
Results
In both groups the total stress evaluation has been mea-
sured by PSM administered before (T0) and after a
cycle of NPPO. In the group A, PSM total score pro-
gressively decreases from 107.8 ± 23.1 at T0 to 87.1 ±
16.2 at T1 (Wilcoxon Signed Rank Test Z = -9.854, p =
0.00; Sign Test Z = -10.132, p = 0.00). On the contrary,
no significant difference has been noted in the group B:
in fact, PSM total score ranged from 107.9 ± 25.8 at T0
to 106.3 ± 25.9 at T1 (Wilcoxon Signed Rank Test Z =
-1.285, p = NS; Sign Test Z = 0.312, p = NS).
In the Group A, the greater improvement between T0
and T1 has been reported on PSM items loss of control,
irritability, psycho-physiological sensations, confusion,
anxiety, depression, physical pain, hyperactivity and agi-
tation (table 1 and figure 1, 2).
Discussion
The use of electricity and magnetic fields in the biome-
dical studies, and in particular in the treatment of dis-
turbances of the nervous system, is not a new idea
[44-47]. Nevertheless modern technology and advanced
knowledge in the physical-medical field and in the neu-
rosciences has allowed realizing the new biomedical
instrument presented in this study.
In the present study we considered a group of patients
treated with REAC and a group with placebo-REAC.
The results suggest that a cycle of NPPO protocol with
REAC reduces the total score of the PSM test (Figure 3,
4) in particular the clusters related to loss of control,
irritability, psycho-physiological sensations, confusion,
anxiety and depression, physical pain, hyperactivity and
agitation (figure 1, 2), and this strictly correlates with a
clinically significant improvement on the subjective per-
ception of stress and stress related symptomatology. On
the other hand, in the placebo-REAC, although the
Table 1 PSM Clusters population in group A and B before and after therapy vs. placebo
PSM Clusters therapy (n = 150) —— placebo (n = 50)
Before After Before After
Loss of control and irritability n = 45 n = 16 p < .05 n = 14 n = 13 p > .05
Psycho Physiological sensation n = 50 n = 11 p < .05 n = 22 n = 20 p > .05
Effort sensation and confusion n = 65 n = 22 p < .05 n = 20 n = 20 p > .05
Anxiety and Depression n = 69 n = 15 p < .05 n = 20 n = 18 p > .05
Pain and Physical trouble n = 68 n = 27 p < .05 n = 30 n = 27 p > .05
Hyperactivity and acceleration n = 27 n = 14 p < .05 n = 12 n = 10 p > .05
Group A show a significantly lower presence of symptomatic clusters after the treatment with p < .05, while Group B show very similar results before and after
treatment p > .05
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Page 3 of 6Figure 1 PSM clusters pre-post NPPO-REAC real treatment, group A. The results show that a cycle of NPPO protocol with REAC reduces
also the PSM symptomatic clusters related to loss of control, irritability, psycho physiological sensations, confusion, anxiety and depression,
physical pain, hyperactivity and acceleration,
Figure 2 PSM clusters pre-post NPPO-REAC placebo treatment, group B. Group B show very similar results before and after a cycle of
NPPO protocol with an inactivated REAC (placebo)
Figure 3 PSM Total score mean value, treated group A. Group A which scored 107.8 ± 23,13 (results are presented as Mean +/- S.D.) show a
significantly lower score of 87.1 ± 16,21 after NPPO-REAC treatment.
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sations on the ear of those with “active” REAC, no sig-
nificant difference in PSM total score was highlighted
between T0 and T1.
A growing number of studies suggests that the stress-
related symptoms are the result of allostatic processes
[12-15,17-19,21-23,25-27,29-31] and our data seems to
indicate that NPPO protocol of REAC treatment is an
effective instrument to ameliorate the responses to allo-
static state and to environmental stressors.
Besides, this treatment has the advantage of being
painless, non-invasive and free of side-effects not only in
the patient groups, but also in the physicians that have
applied this therapy.
The 3:1 proportion between case and controls cer-
tainly represent a bias of this study, mainly in terms of
statistics. However, this has been simply due to the fact
that our Institute is well-known with regard the treat-
ment of psycho-physical stress-related dysfunctions and,
paradoxically, it is been easier to enlist “stressed” than
normal subjects. According to us, the physician’sr o t a -
tion in the different rooms and the fact that each one of
them didn’t known if were administering the “active” or
“placebo” REAC, represent a attempt to achieve more
“scientific” strictness.
Conclusions
We propose that NPPO treatment with REAC will help
to improve the physiological capability of the organism’s
recovery, optimizing the adaptive response to environ-
mental stressors.
Moreover, NPPO treatment with REAC is a non-phar-
macological treatment and can represent an efficient
support in many medical fields, because it does not
interfere with the simultaneous use of other therapeutic
approaches.
Obviously, though these observations on the effective-
ness of NPPO - REAC treatment in the psychometric
evaluation of stress related disorders are certainly
important and suggestive, they are only preliminary and
require further confirmation.
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